Cargando…
Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
The aim of this study was to compare the outcomes of diabetic macular edema (DME) treated with aflibercept (AFB) or ranibizumab (RNB) only, and after switching from RNB to AFB. This was a retrospective, real-world, multicenter (7 cities) 24 month study. Overall, 212 eyes in the AFB group, 461 in the...
Autores principales: | Kucukevcilioglu, Murat, Yeşiltaş, Yağmur Seda, Durukan, Ali Hakan, Unlu, Nurten, Onen, Mehmet, Alp, Mehmet Numan, Kalayci, Defne, Acar, Mehmet Akif, Sekeroglu, Mehmet Ali, Citirik, Mehmet, Altintas, Ayse Gul Kocak, Hazirolan, Dicle, Ozdal, Pinar Cakar, Toklu, Yasin, Bicer, Tolga, Ugurlu, Nagihan, Budakoglu, Ozlem, Yazar, Zeliha, Zeki, Nil Irem Ucgun, Serdar, Kurtulus, Doguizi, Sibel, Erol, Yasemin Ozdamar, Atilgan, Cemile Ucgul, Yorgun, Mucella Arikan, Soba, Dilek Ozcelik, Berker, Nilufer, Baskan, Ceyda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964409/ https://www.ncbi.nlm.nih.gov/pubmed/36837465 http://dx.doi.org/10.3390/medicina59020263 |
Ejemplares similares
-
Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2022) -
Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2023) -
The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018) -
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019) -
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)